Department of Pharmacology and Therapeutics, School of Medicine Clinics Hospital, University of the Republic, Montevideo, Uruguay.
Clin Neuropharmacol. 2022;45(2):27-31. doi: 10.1097/WNF.0000000000000494.
Phytocannabinoid derivatives are among the several compounds found in the cannabis plant. The phytocannabinoid chemicals Δ9-tetrahydrocannabinol (THC) and cannabidiol are mostly responsible for the drug's behavioral effects. Chronic cannabis administration has been shown to disrupt circadian rhythms and reduce the duration of the deepest phase (stage N3) of nonrapid eye movement sleep. Cannabidiol is thought to be responsible for the disruption of the circadian rhythm, whereas THC is thought to be accountable for the changes in sleep architecture. The quality of one's sleep has a significant impact on cannabis abstinence or relapse. As a result, the diminished sleep-promoting efficiency of cannabis in chronic users, as well as the resulting sleep difficulties once cannabis use is stopped, may sabotage attempts to quit and raise the risk of relapse. In individuals with obstructive sleep apnea who do not complain about the treatment process known as continuous positive airway pressure, cannabinoids are one of the treatments being considered. In this regard, preclinical investigations have demonstrated that combining the agent oleamide and THC aids in the stabilization of respiration in all stages of sleep as well as the maintenance of autonomic stability during sleep. The synthetic THC dronabinol was found to lower the apnea-hypopnea index in a clinical investigation and is regarded safe for the short-term treatment of obstructive sleep apnea. Patients experiencing nightmares who had been diagnosed with posttraumatic stress disorder were given the synthetic endocannabinoid receptor agonist nabilone. When compared with a placebo, the chemical proved helpful in reducing the frequency of nightmares. It is worth noting that a single study that looked at the effects of cannabidiol on REM behavior disorder found that symptoms improved. Based on the available findings, cannabinoids can be used as an alternate treatment for various sleep disorders. However, additional research is needed to corroborate the conclusions of these investigations.
植物大麻素衍生物是大麻植物中发现的几种化合物之一。植物大麻素化学物质 Δ9-四氢大麻酚(THC)和大麻二酚主要负责药物的行为效应。慢性大麻给药已被证明会破坏昼夜节律并减少非快速眼动睡眠最深阶段(N3 期)的持续时间。大麻二酚被认为负责破坏昼夜节律,而 THC 被认为负责改变睡眠结构。一个人的睡眠质量对大麻戒断或复发有重大影响。因此,慢性使用者大麻促进睡眠的效率降低,以及一旦停止使用大麻就会出现睡眠困难,这可能会破坏戒烟尝试并增加复发的风险。在不抱怨称为持续气道正压的治疗过程的阻塞性睡眠呼吸暂停患者中,大麻素是正在考虑的治疗方法之一。在这方面,临床前研究表明,联合制剂油酸酰胺和 THC 有助于稳定睡眠各个阶段的呼吸,并在睡眠期间维持自主稳定性。合成的 THC 屈大麻酚在一项临床研究中发现降低了呼吸暂停低通气指数,并且被认为是治疗阻塞性睡眠呼吸暂停的短期安全药物。被诊断患有创伤后应激障碍并经历噩梦的患者被给予合成内源性大麻素受体激动剂 nabilone。与安慰剂相比,该化学物质有助于减少噩梦的频率。值得注意的是,一项研究大麻二酚对 REM 行为障碍的影响的研究发现,症状有所改善。基于现有发现,大麻素可作为各种睡眠障碍的替代治疗方法。然而,需要进一步的研究来证实这些调查的结论。